TRIB

distress 6/10 · elevated risk

$0.28-19%today-85% from 52w high

trinitybiotech.com287 employeesFounded 1992Bray, IrelandMedical Devices

Revenue

$44M

Liquidity

$8M

Runway

1.3 yrs

Shares 1y

Price & events

-64.1% over 6M

CatalystRating changeDilutionFinancingdashed = today

-19.0%

-23.3%

-20.0%

-57.2%

-68.6%

-61.0%

-90.7%

-97.2%

-98.4%

All

Overview

Market Cap: $106.42M
Enterprise Value: $117.62M
Volume: 86.39K
52 Week Range: $0.28 – $1.91
Total Shares: 374.21M
Float Shares: 15.93M
Short %: 7.18%
% Held by Insiders: 16.58%
% Held by Institutions: 5.46%
RVOL: 0.03x
Beta: 1.00

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 0

No catalyst news yet.

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 374,206,640 · 11 offerings/1y · 0 PIPEs

2026-06-23424B3offering
2026-06-18424B3offering
2026-06-15424B3offering
2026-06-12424B5offering
2026-06-10EFFECTshelf_effective
2026-06-03F-1/Ashelf_registration
2026-05-26424B3offering

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

no recent rating changes

Competitors

none identified